Program
crinecerfont
Also written as “Crinecerfont”, “NBI-74788” and “SSR125543”.
Its studies are mostly in Adrenal Hyperplasia, Congenital · Depressive Disorder, Major, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neurocrine Biosciences | 64 open or running | phase 3since Jul 24, 2020 | May 2, 2018 | Mar 2028phase 2 · NCT07536269 |
| Sanofi | 10 open or running | phase 2since Dec 17, 2009 | Dec 17, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 17, 2009First study: phase 2 study in Depressive Disorder, MajorNew to SanofiSanofi · NCT01034995 · 580 enrolled · Belgium, Canada, Chile and more
- May 2, 2018Neurocrine Biosciences's first study: phase 2 study in Adrenal Hyperplasia, CongenitalNew to Neurocrine BiosciencesNeurocrine Biosciences · NCT03525886 · 18 enrolled · United States
- Jul 31, 2019Phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT04045145 · 8 enrolled · United States
- Jul 24, 2020Phase 3 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT04490915 · 182 enrolled · United States, Austria, Belgium and more
- Mar 16, 2021Phase 3 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT04806451 · 103 enrolled · United States, Belgium, Canada and more
- Sep 18, 2025Phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT07187375 · 7 enrolled · Germany
- Apr 10, 2026Phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT07536269 · 20 planned · United States
Ahead
- Mar 2028Primary completion: phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT07536269
- Sep 6, 2029Primary completion: phase 2 study in Adrenal Hyperplasia, CongenitalNeurocrine Biosciences · NCT07187375
TargetBeta
“Corticotropin releasing factor receptor 1 antagonist”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07536269Adrenal Hyperplasia, Congenital · United States | 2 | Recruiting | Neurocrine Biosciences | Mar 2028 | 20 |
| NCT07187375Adrenal Hyperplasia, Congenital · Germany | 2 | Active, not recruiting | Neurocrine Biosciences | Sep 6, 2029 | 7 |
| NCT04806451Adrenal Hyperplasia, Congenital · United States, Belgium, Canada and more | 3 | Active, not recruiting | Neurocrine Biosciences | Mar 10, 2023 | 103 |
| NCT04490915Adrenal Hyperplasia, Congenital · United States, Austria, Belgium and more | 3 | Active, not recruiting | Neurocrine Biosciences | Jul 19, 2023 | 182 |
| NCT04045145Adrenal Hyperplasia, Congenital · United States | 2 | Completed | Neurocrine Biosciences | Jul 2, 2021 | 8 |
| NCT03525886Adrenal Hyperplasia, Congenital · United States | 2 | Completed | Neurocrine Biosciences | Apr 7, 2020 | 18 |
| NCT01034995Depressive Disorder, Major · Belgium, Canada, Chile and more | 2 | Completed | Sanofi | Mar 2011 | 580 |
How it is read
Names in the registry
- “Crinecerfont”, 5 entries
- “NBI-74788”, 1 entry
- “SSR125543”, 1 entry
Conditions, from the studies’ own filings
- Adrenal Hyperplasia, Congenital, 6 studies
- Depressive Disorder, Major, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.